Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171) rose more than 4%, and its general-purpose CAR-T was successively approved to include Kailimei in one million medical insurance

The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose by more than 4%. As of press release, it had risen 4.43% to HK$15.8, with a turnover of HK$266.33,500.

According to the news, Keji Pharmaceutical's general-purpose CAR-T has been approved one after another. On August 4, CT0596, a generic CAR-T product targeting BCMA, was approved for clinical trials by the National Drug Administration for the treatment of relapsed/refractory multiple myeloma. On August 7, CT1190B, a general-purpose CAR-T product targeting the CD19/CD20 dual target, was approved again to treat relapsed/refractory large B-cell lymphoma that failed at least second-line standard treatment.

Notably, Keji Pharmaceuticals' first CAR-T cell treatment product for solid tumors in the world was launched in June 2026. Kailimei made successive breakthroughs in commercial insurance access after going public. Previously, Kailimei was included in the 2026 flagship edition of Good Health Insurance and Long-term Care, and officially came into effect on July 3; on July 22, the cooperation between the company and Zhongan Insurance came into effect.